Previous 10 | Next 10 |
Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeutics HOOKIPA on track to report comprehensive data from oncology and infectious disease programs in the second half of 2021 ...
HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responses A single, intra-tumoral injection of the arenaviral immunotherapeutic resulted in tumor regression in all mice and tumor...
NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release second quarter 2021 financia...
Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.35, breaking its 52-week low. This new low was reached on approximately average trading volume as 481,000 shares traded hands, while the average 30-day volume is approximately 418,000 shares. HOOKIPA Pharma Inc is a clinical ...
Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.44, breaking its 52-week low. So far today approximately 481,000 shares have been exchanged, as compared to an average 30-day volume of 445,000 shares. HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developi...
Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.60, breaking its 52-week low. Approximately 481,000 shares have changed hands today, as compared to an average 30-day volume of 655,000 shares. HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a cla...
Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $8.02, breaking its 52-week low. So far today approximately 481,000 shares have been exchanged, as compared to an average 30-day volume of 643,000 shares. In the past 52 weeks, HOOKIPA Pharma Inc. share prices are bracketed by a...
The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) Investor Presentation -Sildeshow
Today, we revisit HOOKIPA Pharma for the first time in more than a year and a half. The company aims to develop a novel class of immunotherapeutics targeting infectious diseases and cancers based on their proprietary arenavirus platform that works by reprogramming the body's immune sy...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended the day and the week modestly higher Friday, as investors shrugged off a report showing inflation in the U.S. rising 5%, its fas...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com